Related Experiment Video

Updated: May 15, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer

Senthilkumar Damodaran1, Erin M Olson

  • 1James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Hospital Practice (1995)
|January 10, 2013
PubMed

Insights

HER2-positive breast cancer treatment advanced with trastuzumab, but resistance necessitates new therapies. Research explores newer HER2-targeted agents and next-generation treatments for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Amplification of human epidermal growth factor receptor 2 (HER2) is crucial in breast cancer biology.
  • Trastuzumab, a HER2-targeted monoclonal antibody, is a cornerstone therapy for HER2-positive breast cancers.
  • Tumor resistance to trastuzumab drives the need for alternative therapeutic strategies.

Purpose of the Study:

  • To review the molecular biology of the ERbb receptor family.
  • To discuss the clinical application of HER2-targeted agents in early and advanced breast cancer.
  • To explore next-generation anti-HER2 agents in clinical development.

Main Methods:

  • Review of scientific literature on HER2 biology and targeted therapies.
  • Analysis of clinical data regarding trastuzumab and emerging anti-HER2 agents.
  • Examination of molecular mechanisms of HER2 receptor family interactions.

Main Results:

  • HER2 amplification significantly impacts breast cancer progression and treatment response.
  • Trastuzumab offers substantial benefits in metastatic HER2-positive breast cancer but is subject to resistance.
  • Newer HER2-directed agents and combination therapies are expanding treatment options.

Conclusions:

  • Understanding ERbb family interactions is key to developing novel HER2-targeted therapies.
  • Overcoming trastuzumab resistance is critical for improving long-term outcomes in HER2-positive breast cancer.
  • Ongoing research into next-generation anti-HER2 agents promises to enhance the therapeutic armamentarium.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...